within Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AX16_Eflornithine;

model Eflornithine
  extends Pharmacolibrary.Drugs.ATC.D.D11AX16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D11AX16</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Eflornithine is an irreversible inhibitor of ornithine decarboxylase, originally developed and approved for the treatment of West African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense. It is also used topically to slow facial hair growth in women (in cream formulations). The intravenous form is on the WHO List of Essential Medicines, but its use is primarily in specific infectious diseases rather than general clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with African trypanosomiasis following intravenous administration.</p><h4>References</h4><ol><li><p>Boberg, M, et al., &amp; Ashton, M (2021). Enantiospecific antitrypanosomal in vitro activity of eflornithine. <i>PLoS neglected tropical diseases</i> 15(7) e0009583–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pntd.0009583&quot;>10.1371/journal.pntd.0009583</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34252098/&quot;>https://pubmed.ncbi.nlm.nih.gov/34252098</a></p></li><li><p>Amilon, C, et al., &amp; Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. <i>The AAPS journal</i> 24(3) 48–None. DOI:<a href=&quot;https://doi.org/10.1208/s12248-022-00693-2&quot;>10.1208/s12248-022-00693-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35338410/&quot;>https://pubmed.ncbi.nlm.nih.gov/35338410</a></p></li><li><p>Jansson, R, et al., &amp; Ashton, M (2008). Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. <i>Antimicrobial agents and chemotherapy</i> 52(8) 2842–2848. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00050-08&quot;>10.1128/AAC.00050-08</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18519728/&quot;>https://pubmed.ncbi.nlm.nih.gov/18519728</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Eflornithine;
